<DOC>
	<DOCNO>NCT02749097</DOCNO>
	<brief_summary>This randomize , placebo-controlled , single dose escalation study investigate safety , tolerability , pharmacokinetics pharmacodynamics SHR0534 . The study conduct start dose 10 mg follow dose escalation group 200 mg . Eight subject randomize 3:1 ratio cohort receive study drug placebo .</brief_summary>
	<brief_title>A PHASE I , RANDOMIZED , PLACEBO-CONTROLLED , SINGLE DOSE ESCALATION STUDY TO INVESTIGATE SAFETY , PHARMACOKINETICS AND PHARMACODYNAMICS OF SHR0534 IN HEALTHY VOLUNTEERS</brief_title>
	<detailed_description />
	<criteria>Subject must adequately inform nature risk study , able understand risk associate study , willing provide write informed consent prior screen . Must least 50 kg ( 110 lb ) , BMI 19.0 32.0 kg/m2 , inclusive . Drug screen ( include alcohol ) must negative Screening admission study site . Subjects must free clinically significant disease base medical history , physical examination and/or investigator 's judgment Clinical laboratory test ( i.e . CBC , platelet count , blood chemistry , urinalysis ) must within normal reference range clinically acceptable determined investigator . Completion screen process within 14 day prior dose . Must able communicate effectively study personnel . Must nonsmoker , define smoked tobacco use chew tobacco nicotinecontaining product 6 month prior Day 1 . Cotinine test must negative Screening Day 1 . Must , investigator 's opinion , clinically significant disease abnormal laboratory test value determine medical psychiatric history , physical examination , laboratory evaluation conduct screen visit clinic admission . Subjects reproductive potential partner woman childbearing potential , instructed , must willing practice highly effective method birth control duration study continue 90 day discontinue treatment investigational product . Highly effective method birth control include sexual abstinence , vasectomy condom spermicide ( men ) combination barrier method , oral , injected , implanted hormonal birth control method , placement intrauterine device intrauterine system ( female partner ) . Subjects must agree donate sperm study 90 day discontinue treatment investigational product . History hypersensitivity SHR0534 component . History current clinically important systemic illness , include limited cardiovascular , pulmonary , hepatobiliary , renal , hematological , gastrointestinal , endocrinological , immunological , dermatological , neurological , psychiatric disease , condition may place subject increase risk determine investigator . Any condition know interfere absorption , distribution , metabolism , excretion drug . History surgery major trauma within 12 week study entry , surgery plan study . History allergy hypersensitivity heparin , heparininduced thrombocytopenia . History myocardial infarction , stroke sudden unexplained death first degree family member age 60 year . History liver disease . Those ALT AST &gt; 1.5 time upper limit normal must exclude . Subjects anemia abnormal hematology parameter clinically significance determined investigator must exclude . History presence clinically significant electrocardiogram ( ECG ) abnormality . History alcohol dependent , habitual heavy user caffeinated beverage judge investigator . Have use alcoholcontaining product within 3 day Day 1 . Urine drug screen test positive ethanol , cocaine , tetrahydrocannabinol ( THC ) , barbiturates , amphetamine , benzodiazepine , opiate . Have use drug substance ( include herbal supplement ) know inhibit induce cytochrome ( CYP ) P450 enzymes include CYP3A4 , CYP2C8 CYP2C9 within 28 day prior first dose throughout study . Use overthecounter ( OTC ) , nutraceuticals , prescription medication ( except specify within protocol ) within 7 day 5 half life ( whichever longer ) , prior receive investigational product . By exception , 2 g per day acetaminophen ( paracetamol ) analgesia allow 48 hour prior Day 1 . Use xanthinecontaining substance , alcoholcontaining product within 48 hour prior study drug administration . Use grapefruit relate citrus fruit product 7 day prior study drug administration intend use study . Have take investigational drug participate clinical trial within 30 day prior first dose study drug study . Have significant blood loss ( &gt; 450 mL ) donate 1 unit blood plasma within 12 week prior study entry . Have positive test Screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) . Have condition prior therapy , investigator 's opinion , would make subject unsuitable study , unable unwilling comply study procedure . Any individual involved planning conduct study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>